mirikizumab (LY3074828) - Eli Lilly
Mirikizumab: Primary completion of P3 LUCENT 2 trial (NCT03524092) in moderate-to-severe ulcerative colitis in Jun 2021 (Eli Lilly) - Oct 23, 2019 - Q3 2019 Results: Completion of P3 LUCENT 2 trial in moderate-to-severe ulcerative colitis in Jun 2023; Primary completion and completion of P3 LUCENT 3 trial (NCT03519945) in moderate-to-severe ulcerative colitis in Aug 2023 
Trial completion date • Trial primary completion date
https://investor.lilly.com/static-files/c4eae44d-aea0-4f4b-90d9-d7e6d86412af
 
Oct 23, 2019
 
 
b704c300-18cf-4ba8-aaea-8f193b619edf.jpg